

Supplementary Table 4. Baseline characteristics and changes in HbA1c and body weight according to the kinds of SGLT2 inhibitors

Variable	Empagliflozin users (n=128)	Dapagliflozin users (n=500)	Ipragliflozin users (n=176)	P value
Age, yr	56 (47–63)	56 (49–63)	59 (51–66)	0.002
Male sex	92 (71.9)	246 (49.2)	99 (56.3)	<0.001
DM duration, yr	5.4 (2.3–9.8)	8.9 (4.6–12.2)	5.4 (2.3–8.5)	<0.001
Body mass index, kg/m ²	26.7 (24.2–29.3)	27.7 (25.3–30.8)	26.8 (24.5–29.6)	0.024
HbA1c, %	7.7 (7.0–8.6)	7.8 (7.2–8.7)	7.4 (6.8–8.1)	<0.001
FPG, mg/dL	146 (128–178)	156 (132–186)	145 (124–164)	0.003
PP2, mg/dL	243 (190–285)	242 (196–291)	222 (185–274)	0.109
Total cholesterol, mg/dL	161 (135–181)	163 (144–186)	168 (140–193)	0.281
Triglyceride, mg/dL	162 (113–208)	141 (103–206)	151 (106–217)	0.293
HDL-C, mg/dL	44 (38–51)	44 (27–40)	44 (37–53)	0.977
LDL-C, mg/dL	82 (64–99)	86 (68–108)	85 (67–110)	0.077
BUN, mg/dL	14.8 (12.1–18.2)	14.4 (11.8–17.3)	14.9 (11.5–17.2)	0.371
Creatinine, mg/dL	0.8 (0.7–1.0)	0.7 (0.6–0.9)	0.8 (0.7–0.9)	<0.001
eGFR, mL/min/1.73 m ²	100 (84–115)	103 (90–120)	99 (87–114)	0.029
AST, IU/L	24 (18–32)	23 (18–37)	24 (18–36)	0.948
ALT, IU/L	28 (17–48)	30 (20–50)	29 (20–46)	0.715
Change from baseline HbA1c, %	-0.5 (-1.2 to 0)	-0.5 (-1.3 to 0)	-0.5 (-1.0 to 0)	0.629
Changes in body weight, %	3.5 (1.2–6.3)	4.1 (1.4–6.9)	3.5 (0.0–6.0)	0.125

Values are presented as median (interquartile range) or number (%). Change from baseline HbA1c (%) was calculated as (follow-up HbA1c–baseline HbA1c) and changes in body weight (%) were calculated as [(baseline body weight–follow-up body weight)/baseline body weight] × 100.

HbA1c, glycosylated hemoglobin; SGLT2, sodium-glucose co-transporter 2; DM, diabetes mellitus; FPG, fasting plasma glucose; PP2, post-prandial 2-hour glucose; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol; BUN, blood urea nitrogen; eGFR, estimated glomerular filtration rate; AST, aspartate aminotransferase; ALT, alanine aminotransferase.